Page last updated: 2024-11-05

fluorescein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fluorescein is a synthetic xanthene dye that exhibits strong green fluorescence when excited with blue light. It is widely used in various applications, including microscopy, diagnostics, and tracing. Fluorescein is synthesized through a multi-step process involving the condensation of resorcinol and phthalic anhydride. It is often used as a tracer in biological studies to visualize the flow of fluids or to label cells and tissues. Fluorescein is also a key component in fluorescent microscopy techniques, such as confocal microscopy and fluorescence in situ hybridization (FISH), which allow for the visualization of specific structures or molecules within cells or tissues. The fluorescence properties of fluorescein are sensitive to environmental factors such as pH and polarity, making it useful for sensing applications. Moreover, fluorescein derivatives have been developed for targeted drug delivery and photodynamic therapy, highlighting its potential in medical research and treatment.'

Fluorescein: A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium such as the aqueous humor. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fluorescein (lactone form) : A xanthene dye that is highly fluorescent, detectable even when present in minute quantities. Used forensically to detect traces of blood, in analytical chemistry as an indicator in silver nitrate titrations and in microscopy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16850
CHEMBL ID1057
CHEBI ID31624
SCHEMBL ID16533
MeSH IDM0029368

Synonyms (159)

Synonym
c.i. solvent yellow 94
d and c yellow no. 7
3',6'-dihydroxyspiro[isobenzofuran-3,9'-xanthene]-1-one
2321-07-5
fluorescein
3',6'-dihydroxyspiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one
CHEMBL1057 ,
c20h12o5
fluorescein (free acid)
diofluor
nsc667256
nsc-667256
brn 0094324
fluorescein acid
fluorescein red
soap yellow f
11712 yellow
nsc 667256
d+c yellow no. 7
3',6'-dihydroxyspiro(isobenzofuran-1(3h),9'(9h)-xanthen)-3-one
japan yellow no. 201
benzoic acid, o-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-
einecs 219-031-8
c.i. 45350:1
hsdb 2128
fluoran, 3',6'-dihydroxy-
spiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one,3'6'-dihydroxy-
3,6-dihydroxyspiro(xanthene-9,3'-phthalide)
3h-xanthen-3-one, 9-(o-carboxyphenyl)-6-hydroxy-
ci 45350:1
d & c yellow no. 7
benzoic acid, 2-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-
zlut kysela 73 [czech]
ccris 7076
spiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one, 3',6'-dihydroxy-
2-(6-hydroxy-3-oxo-(3h)-xanthen-9-yl)benzoic acid
hidacid fluorescein
resorcinolphthalein
3',6'-dihydroxy-3h-spiro[2-benzofuran-1,9'-xanthen]-3-one
9-(o-carboxyphenyl)-6-hydroxy-3-isoxanthenone
d&c yellow no. 7
3',6'-dihydroxyfluoran
CHEBI:31624 ,
yellow fluorescein
japan yellow 201
9-(o-carboxyphenyl)-6-hydroxy-3h-xanthen-3-one
3,6-fluorandiol
solvent yellow 94
fluoresceine
fluoreszein
UPCMLD-DP087:001
MOLI001003
fluorescein (free acid), dye content 95 %
DB00693
UPCMLD-DP087
NCGC00161643-02
fluorescite (tn)
D01261
fluorescein (jan/usp)
NCGC00161643-01
HMS2093F21
E89FA0B4-4844-46A2-AF9B-29ECA50E5599
inchi=1/c20h12o5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22h
gnbhrkfjiuuoqi-uhfffaoysa-
3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
FT-0668579
F0095
NCGC00161643-03
5-19-06-00456 (beilstein handbook reference)
ec 219-031-8
tpy09g7xir ,
unii-tpy09g7xir
zlut kysela 73
fluorescein [usp:ban:jan]
dtxsid0038887 ,
tox21_303508
dtxcid8018887
NCGC00257491-01
cas-2321-07-5
tox21_113500
pharmakon1600-01505396
nsc759114
nsc-759114
3',6'-dihydroxy-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one
fluorescein [usp-rs]
yellow 7 [inci]
fluorescein [ep monograph]
fluorescein [vandf]
ki201 [inci]
fluorescein [hsdb]
fluorescein [who-dd]
fluorescein [ii]
d & c yellow no. 7 k7133
acid yellow 73 [inci]
fluorescein [mart.]
fluorescein [usp monograph]
fluorescein [jan]
ki201
fluorescein [mi]
EPITOPE ID:137337
AKOS015903296
S5488
CCG-213417
SCHEMBL16533
W-107417
CS-7537
spiro[isobenzofuran-1(3h),9'-[9h]xanthen]-3-one, 3',6'-dihydroxy-
3,6-dihydroxyspiro[xanthene-9,3'-phthalide]
c.i. 45350 (salt/mix)
c.i. acid yellow 73 (salt/mix)
dihydroxyfluorane
3',6'-fluorandiol
fluorescite (salt/mix)
c.i. 45350a
diresorcinolphthalein
AB00643381_02
mfcd00005050
bdbm50237588
resorcinol phthalein
SR-05000001696-1
sr-05000001696
fluorescein, for fluorescence, free acid
fluorescein low range dna standard, fluorescein-labeled marker for dna electrophoresis
fluorescein, united states pharmacopeia (usp) reference standard
fluorescein, european pharmacopoeia (ep) reference standard
SBI-0206827.P001
HY-D0251
Q410922
3',6' dihydroxyfluoran
3',6'-dihydroxy-3h-spiro[isobenzo[b]furan-1,9'-xanthen]-3-one
AMY22388
BRD-K21913543-001-01-6
HMS3744C17
D70685
fluorescein (solvent yellow 94)
SY012645
EN300-702817
spiro[isobenzofuran-1(3h),9'-[9h]xanthene]-ar-carboxylicacid, 3',6'-dihydroxy-3-oxo-
BP-31220
3',6'-dihydroxyspiro(isobenzofuran-1(3h), 9'(9h)-xanthen)-3-one
o-(6-hydroxy-3-oxo-3h-xanthen-9-yl)benzoic acid
fluorescein (lactone form)
benzoic acid, o-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-,
fluorescein lactone
spiro(isobenzofuran-1(3h),9'-(9h)xanthen-3-one, 3',6'-dihydroxy-
fluoresceina
fluorescein (mart.)
fluorescein (usp:ban:jan)
3',6'-dihydroxyfluorane
fluorescein (usp monograph)
fluorescein (usp-rs)
3',4'-dehydroxyfluoran
fluorescein (ep monograph)
fluorescein (ii)
d&c yellow no 7
11712 yellow9-(o-carboxyphenyl)-6-hydroxy-3h-xanthen-3-one
c.i. 45350 (free acid)
3',6'-dihydroxy-3h-spiro(2-benzofuran-1,9'-xanthen)-3-one
benzoic acid, 2-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-,

Research Excerpts

Overview

Fluorescein is an agent that accumulates in areas of blood-brain barrier breakdown. It is commonly used in neurosurgical oncology to assist with lesion localization and visualizing the extent of resection.

ExcerptReferenceRelevance
"Fluorescein is an agent that accumulates in areas of blood-brain barrier breakdown and is commonly used in neurosurgical oncology to assist with lesion localization and visualizing the extent of resection. "( Headlight and loupe-based fluorescein detection system in brain tumor surgery: a first-in-human experience.
Amankulor, NM; Habib, A; Jaman, E; Mallela, AN; Zhang, X; Zinn, PO, 2023
)
2.65
"Fluorescein is a helpful microsurgical tool in guiding surgical resection and in the localization of intramedullary spinal lesions."( Application of sodium fluorescein for spinal cord lesions: intraoperative localization for tissue biopsy and surgical resection.
Chatain, GP; Finn, M; Serva, S; Ung, TH; Witt, JP, 2022
)
1.76
"Fluorescein fluorescence is a handy tool to detect the pathological tissue in stereotactic brain biopsy and may improve its diagnostic accuracy and expedite the procedure."( Fluorescein sodium fluorescence: role in stereotactic brain biopsy.
Ahmad, F; Kaif, M; Khan, KA; Kumar Singh, R; Singh, AK; Singh, DK; Yadav, K, 2023
)
3.8
"Fluorescein is a fluorescent dye used as a diagnostic tool in various fields of medicine. "( Antiproliferative and Cytotoxic Activities of Fluorescein-A Diagnostic Angiography Dye.
Dvořák, A; Klán, P; Martínek, M; Muchová, L; Šebej, P; Šranková, M; Vítek, L, 2022
)
2.42
"Fluorescein angiography is an important and frequently used diagnostic tool in ophthalmological practice. "( Systemic reaction to and interference with urine protein measurements after intravenous fluorescein injection.
Bouman, AC; de Kruijf, D; Emmen, JMA; Faes, MC; Groot, MJCK; Rettig, TCD, 2019
)
2.18
"Fluorescein is an inexpensive fluorescent lymphatic tracer."( Low-cost Fluorescein as an Alternative to Radio-colloid for Sentinel Lymph Node Biopsy-a Prospective Validation Study in Early Breast Cancer.
Agarwal, A; Agarwal, G; Agrawal, V; Chand, G; Gambhir, S; Mayilvaganan, S; Mishra, A; Mishra, SK; Valiveru, RC, 2020
)
1.7
"Fluorescein is a helpful supplement in the neurosurgical treatment of cerebral metastases."( Fluorescein-guided resection of cerebral metastases is associated with greater tumor resection.
Halle, B; Hansen, RW; Kofoed, MS; Kristensen, BW; Markovic, L; Pedersen, CB; Poulsen, FR; Schulz, MK, 2022
)
3.61
"Fluorescein guidance is a feasible tool for defining surgical entry zones when aiming for surgical removal of spinal cord and brain stem lesions. "( Where and When to Cut? Fluorescein Guidance for Brain Stem and Spinal Cord Tumor Surgery-Technical Note.
Stummer, W; Suero Molina, E, 2018
)
2.23
"Fluorescein sodium is a safe dye; it can be used to aid in precise localization and safe maximal resection of the pathologic tissue with the help of a blue light source at any center with challenged resources. "( Simple Improvisation to Enhance Utility of Fluorescein Sodium in Resection of Intracranial Lesions at Routine Neurosurgical Centers.
Ginjupally, DR; Gollapudi, PR; Kotha, AR; Mohammed, I; Pittala, SR; Reddycherla, NR, 2018
)
2.19
"Fluorescein is a chemical dye frequently used in eye diseases to assess blood flow in the retina, choroid tissue, and iris. "( Fluorescein-related extensive jaundice.
Aydin, I; Kalkan, A; Turedi, S, 2015
)
3.3
"Fluorescein sodium is a fluorescent tracer used for retinal and neurosurgical angiography but not yet for lymphatic supermicrosurgery."( Fluorescein sodium fluorescence microscope-integrated lymphangiography for lymphatic supermicrosurgery.
Ayestaray, B; Bekara, F, 2015
)
2.58
"Fluorescein is a representative green fluorophore that has been widely used as a scaffold of practically useful green fluorescent probes. "( Analysis of chemical equilibrium of silicon-substituted fluorescein and its application to develop a scaffold for red fluorescent probes.
Egawa, T; Hanaoka, K; Hirabayashi, K; Kamiya, M; Komatsu, T; Nagano, T; Takayanagi, T; Terai, T; Toki, Y; Uchiyama, M; Ueno, T; Urano, Y; Yoshida, K, 2015
)
2.11
"Fluorescein dye is a sensitive test for determining native mastectomy skin flap viability after autologous reconstruction; however, viability is underpredicted. "( The use of fluorescein dye as a predictor of mastectomy skin flap viability following autologous tissue reconstruction.
Carlson, GW; Losken, A; Schaefer, TG; Styblo, TM, 2008
)
2.18
"Fluorescein is a fluorochrome dye occasionally administered by intrathecal injection to identify and localize cerebrospinal fluid leaks. "( Status epilepticus and intrathecal fluorescein: anesthesia providers beware.
Dilger, JA; Hebl, JR; Jacob, AK, 2008
)
2.07
"Fluorescein sodium is a fluorescent molecule that has been used specifically in ophthalmology for the treatment of retinal angiography. "( Technical principles and neurosurgical applications of fluorescein fluorescence using a microscope-integrated fluorescence module.
Cohen-Gadol, AA; Rey-Dios, R, 2013
)
2.08
"Fluorescein is a marker-dye customary applied to the evaluation of tight-junctional permeability of epithelial cell monolayers. "( Transepithelial transport of fluorescein in Caco-2 cell monolayers and use of such transport in in vitro evaluation of phenolic acid availability.
Hagiwara, K; Konishi, Y; Shimizu, M, 2002
)
2.05
"Fluorescein is a widely used fluorescent probe in DNA analysis. "( Enhanced emission of highly labeled DNA oligomers near silver metallic surfaces.
Gryczynski, I; Lakowicz, JR; Malicka, J, 2003
)
1.76
"Fluorescein angiography is a relative safe procedure and comparable to other intravenous radiocontrast media angiography or investigation. "( Fluorescein angiography and adverse drug reactions revisited: the Lions Eye experience.
Barry, C; Constable, I; Kwan, AS; McAllister, IL,
)
3.02
"Fluorescein is a simple and rapid means of evaluating traumatized intestine, and it may prove to be a useful adjunct to the clinical examination."( Evaluation of injured intestine with the aid of fluorescein.
Brotman, S; Cowley, RA; Marzella, L; Mayer, J, 1984
)
1.24
"[fluorescein Lys3]SP is an agonist at the human NK1 receptor, with an affinity for both the high-affinity and low-affinity binding states of the receptor approximately 6-fold lower than that of substance P."( Characterization of a fluorescent substance P analog.
Daniel, S; Fong, TM; Longmore, J; Mazina, KE; Sirotina, A; Strader, CD; Tota, MR, 1994
)
0.91
"Fluorescein is an effective dye for immediate and transient localization of trans-scleral transplants to the subretinal space. "( Fluorescein as a marker for subretinal transplantation of human fetal neural retina.
Cox, C; Das, T; del Cerro, C; del Cerro, M; DiLoreto, DA, 1997
)
3.18
"Fluorescein and Cy3 are an important donor-acceptor pair of fluorophores; the characteristic Förster length for this pair on DNA is 56 A, so the pair can be used to study relatively long distances."( Location of cyanine-3 on double-stranded DNA: importance for fluorescence resonance energy transfer studies.
Grainger, RJ; Lilley, DM; Norman, DG; Uhrín, D, 2000
)
1.03
"Oral fluorescein angiography is an efficient and highly sensitive tool for the detection of macular oedema. "( Use of oral fluorescein angiography in the diagnosis of macular oedema within a diabetic retinopathy screening programme.
Kritzinger, EE; Razvi, FM; Ryder, RE; Tsaloumas, MD, 2001
)
1.2
"Fluorescein angiography is a routine procedure in ophthalmology. "( Carpopedal spasm: an unusual reaction to fluorescein?
Mole, T, 1991
)
1.99
"Fluorescein angiography is an application of the physical phenomenon of fluorescence, which is phosphorescence in which the quantum mechanical decay curve is so rapid that it appears instantaneous, and it consequently has no afterglow. "( Fluorescein angiography basic science and engineering.
Wolfe, DR, 1986
)
3.16

Effects

Fluorescein has a significantly low distribution in the brain. It has an extremely low luminescence intensity in acidic aqueous media.

Fluorescein dye has been used for tumour detection in colon, stomach, breast and brain. It has a significantly low distribution in the brain (contrast with the level in adipose tissue)

ExcerptReferenceRelevance
"Fluorescein has a significantly low distribution in the brain (contrast with the level in adipose tissue indicates the low ability to penetrate the blood-brain barrier)."( Pharmacokinetics and organ distribution of fluorescein in experimental pigs: an input study for confocal laser endomicroscopy of the gastrointestinal tract.
Bures, J; Kopacova, M; Kunes, M; Kvetina, J; Malakova, J; Rejchrt, S, 2010
)
1.34
"Fluorescein has an extremely low luminescence intensity in acidic aqueous media. "( Highly sensitive and simple fluorescence staining of proteins in sodium dodecyl sulfate-polyacrylamide-based gels by using hydrophobic tail-mediated enhancement of fluorescein luminescence.
Jung, DY; Kang, C; Kang, D; Kim, HJ; Suh, M, 2003
)
1.96
"Fluorescein dye has been used for tumour detection in colon, stomach, breast and brain."( NOVEL USE OF FLUORESCEIN DYE IN DETECTION OF ORAL DYSPLASIA AND ORAL CANCER.
Bhatt, K; Gupta, SD; Kharbanda, OP; Kumawat, R; Mishra, D; Pandey, RM; Qaiser, D; Sood, A; Srivastava, A; Yadav, R, 2020
)
1.65
"Fluorescein has recently been reintroduced into neurosurgery, and novel microscope systems are available for visualizing this fluorochrome, which highlights all perfused tissues but has limited selectivity for tumor detection."( Dual-labeling with 5-aminolevulinic acid and fluorescein for fluorescence-guided resection of high-grade gliomas: technical note.
Brokinkel, B; Ehrhardt, A; Ewelt, C; Stummer, W; Suero Molina, E; Wölfer, J, 2018
)
1.46
"Fluorescein has been found as an efficient visible-light-induced oxidase mimic and its catalytic performance is group-dependent. "( New optical method for the determination of β-galactosidase and α-fetoprotein based on oxidase-like activity of fluorescein.
Gao, C; Liao, B; Liu, L; Shi, Y; Sun, C; Tang, M; Zhang, X; Zheng, H, 2019
)
2.17
"Fluorescein has been used for rapid and sensitive detection of fish skin and corneal ulceration. "( The effect of tricaine on use of the fluorescein test for detecting skin and corneal ulcers in fish.
Davis, MW; Noga, EJ; Stephenson, J, 2008
)
2.06
"This fluorescein variant has two readily accessible functional groups (aniline NH2 and phenol OH) that can be activated or blocked independently and can serve, for instance, as a fluorescent bridge between two different recognition motifs."( A photostable, pH-invariant fluorescein derivative for single-molecule microscopy.
Avadisian, M; Fletcher, S; Gradinaru, CC; Gunning, PT; Liu, B, 2009
)
1.1
"Fluorescein has a significantly low distribution in the brain (contrast with the level in adipose tissue indicates the low ability to penetrate the blood-brain barrier)."( Pharmacokinetics and organ distribution of fluorescein in experimental pigs: an input study for confocal laser endomicroscopy of the gastrointestinal tract.
Bures, J; Kopacova, M; Kunes, M; Kvetina, J; Malakova, J; Rejchrt, S, 2010
)
1.34
"Fluorescein has also been conjugated to rat plasma proteins."( Fluorescein-conjugated bovine albumin; physical and biological properties.
HESS, EL; SCHAYER, RW; SCHILLER, AA, 1953
)
2.4
"Fluorescein has an extremely low luminescence intensity in acidic aqueous media. "( Highly sensitive and simple fluorescence staining of proteins in sodium dodecyl sulfate-polyacrylamide-based gels by using hydrophobic tail-mediated enhancement of fluorescein luminescence.
Jung, DY; Kang, C; Kang, D; Kim, HJ; Suh, M, 2003
)
1.96
"Fluorescein has been used for many years in medicine for diagnostic purposes and is widely safe, albeit intravenous bolus injection may cause serious adverse reactions. "( Safety of sodium fluorescein for in vivo study of skin.
O'goshi, K; Serup, J, 2006
)
2.12
"Fluorescein sodium has been used in 13 cases, and achieved effective stainability in all cases."( Metastatic brain tumor surgery using fluorescein sodium: technical note.
Kataoka, K; Okuda, T; Taneda, M, 2007
)
1.33
"Fluorescein staining has been used to assess the viability of many tissues, and in the present study discolouration was compared with fluorescein staining."( The value of fluorescein for predicting viability muscle tissue after high-energy trauma.
Holmström, A, 1984
)
1.36
"Fluorescein has been shown to meet these requirements."( Fluorescein as a label for non-radioactive in situ hybridization.
Brunning, S; Chadwick, P; Cunningham, M; Durrant, I; Eccleston, L, 1995
)
2.46
"Fluorescein has been shown not to hinder the hairpin formation and to give an additional protection against nucleases."( Fluorescence resonance energy transfer analysis of the degradation of an oligonucleotide protected by a very stable hairpin.
Chinsky, L; Jollès, B; Laigle, A; Réfrégiers, M, 1996
)
1.02
"Fluorescein diffusion has been expressed by different parameters with reported coefficients of variation of 14-20%."( Improved reproducibility of the 'large-window' method of assessing transcapillary and interstitial fluorescein diffusion in the skin in healthy subjects and in subjects with insulin-dependent diabetes mellitus.
Jager, J; Oomen, PH; Reitsma, WD; Sluiter, WJ; Smit, AJ,
)
1.07
"Fluorescein has been used in the field of neurosurgery; however, fluorescein enhancement or contrast proved to be inadequate because of a lack of appropriate light sources or filters. "( Development of a fluorescein operative microscope for use during malignant glioma surgery: a technical note and preliminary report.
Kajimoto, Y; Kuroiwa, T; Ohta, T, 1998
)
2.08
"Fluorescein has proved to be consistent and reliable, and the dermofluorometer has the advantage of using smaller fluorescein doses that can be frequently repeated."( Flap physiology and the prediction of flap viability.
Reinisch, JF; Sloan, GM, 1985
)
0.99

Actions

ExcerptReferenceRelevance
"Fluorescein did not cause any significant change in the NITBUT of HK-Chinese and the instillation of fluorescein in one eye does not affect the NITBUT of the fellow eye."( Effect of fluorescein on the tear stability of Hong Kong-Chinese.
Brown, B; Cho, P; Lau, C, 1996
)
1.42

Toxicity

Injection of fluorescein intravenously for fundal angiography is associated with a high incidence of minor adverse effects (21%) but a very low incidence of serious (life threatening) reactions (0%).

ExcerptReferenceRelevance
"Injection of fluorescein intravenously for fundal angiography is associated with a high incidence of minor adverse effects (21%) but a very low incidence of serious (life threatening) reactions (0."( Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules.
Rosen, ES; Watson, AP, 1990
)
1.16
"The penetration of sulforhodamine B (SRB) into the two corneas of a freshly killed mouse was measured after one eye was briefly exposed to a solution of a possibly toxic substance."( A permeability test for acute corneal toxicity.
Maurice, D; Singh, T, 1986
)
0.27
" In 1,787 patients, no anaphylactic or other severe adverse effects were observed, and only 31 patients (1."( Efficacy and safety of fluorescein angiography with orally administered sodium fluorescein.
Hara, T; Inami, M, 1998
)
0.61
"Fluorescein angiography using orally administered sodium fluorescein is generally effective and safe in standard clinical practice."( Efficacy and safety of fluorescein angiography with orally administered sodium fluorescein.
Hara, T; Inami, M, 1998
)
2.05
" We describe a safe method of introducing fluorescein into the thecal space."( Use of fluorescein for detecting cerebrospinal fluid rhinorrhoea: A safe technique for intrathecal injection.
Bateman, N; Jones, NS; Mason, J,
)
0.85
" Side effect incidence and patient and investigator opinions were also recorded."( Tolerability and safety of 0.1% diclofenac plus 0.3% tobramycin fixed-dose ophthalmic solution: a randomized, comparative, controlled study in healthy volunteers.
Andreu, D; Costa, J; Martínez, M; Notivol, R; Salvá, P, 1999
)
0.3
"NaFl stained the peripheral uncut clear vitreous green and improved the visualization for a safe and complete vitrectomy."( Intravitreal sodium fluorescein enhances visualization of clear vitreous during vitreous surgery for macular hole: a safety and efficacy study.
Das, T; Vedantham, V, 2004
)
0.65
"40%, and FS 10% appeared to be safe as determined by no cytotoxic effects on rabbit corneal endothelial cells in culture."( Comparison of dyes for cataract surgery. Part 1: cytotoxicity to corneal endothelial cells in a rabbit model.
Chang, YS; Chen, YT; Hsiao, JH; Tseng, SH; Tseng, SY, 2005
)
0.33
"Side effects or adverse events reported in the literature were related to intravenous bolus injection."( Safety of sodium fluorescein for in vivo study of skin.
O'goshi, K; Serup, J, 2006
)
0.67
"Fluorescein has been used for many years in medicine for diagnostic purposes and is widely safe, albeit intravenous bolus injection may cause serious adverse reactions."( Safety of sodium fluorescein for in vivo study of skin.
O'goshi, K; Serup, J, 2006
)
2.12
" Heart rate, oximetry measurement and adverse reactions did not show any significant statistical differences between both groups."( [Angiography: safety x economy].
Casella, AM; Frecceiro, PR; Luchini, A; Muccioli, C; Regonha, E; Torres, RJ; Weiss, W,
)
0.13
" However, it did not have any influence on heart rate, oximetry or adverse reactions such as nausea, vomiting, syncope and rashes."( [Angiography: safety x economy].
Casella, AM; Frecceiro, PR; Luchini, A; Muccioli, C; Regonha, E; Torres, RJ; Weiss, W,
)
0.13
" The objective of this study was to demonstrate that the toxic effect of mitochondrial aerobic pathway inhibition with MPP(+ )can be reduced by stimulating anaerobic glycolysis using glucose supplementation."( Anaerobic glycolysis protection against 1-methy-4-phenylpyridinium (MPP+) toxicity in C6 glioma cells.
Goodman, CB; Soliman, KF; Williams, ZR, 2007
)
0.34
" Daily wear soft lens wearers should be routinely examined with sodium fluorescein soon after lenses are inserted and alternative solution/lens type combinations should be investigated if toxic staining is detected."( Solution toxicity in soft contact lens daily wear is associated with corneal inflammation.
Carnt, N; Jalbert, I; Naduvilath, T; Papas, E; Stretton, S, 2007
)
0.57
" Initial tests on transformed human corneal epithelial (HCE-T) cells in monolayer cultures resulted in adverse effects on cell morphology."( Corneal epithelial testing strategies for safety evaluation of ophthalmic formulations.
Choi, JH; Clousing, DP; Edelhauser, HF; Hoffman, HM; McCarey, BE; Ubels, JL, 2007
)
0.34
"Although intravenous fluorescein angiography (IVFA) is a relatively safe procedure, side effects have been shown to occur."( Evaluation of the side effects and image quality during fluorescein angiography comparing 2 mL and 5 mL sodium fluorescein.
Moosbrugger, KA; Sheidow, TG, 2008
)
0.91
"A prospective study was initiated in which 1200 patients were randomized to 2 mL or 5 mL of 10% NaFl to allow for the evaluation of adverse events."( Evaluation of the side effects and image quality during fluorescein angiography comparing 2 mL and 5 mL sodium fluorescein.
Moosbrugger, KA; Sheidow, TG, 2008
)
0.59
" Patients randomized to the 5 mL NaFl group experienced all 3 of the minor adverse events in the study."( Evaluation of the side effects and image quality during fluorescein angiography comparing 2 mL and 5 mL sodium fluorescein.
Moosbrugger, KA; Sheidow, TG, 2008
)
0.59
" The potential reduction in adverse events associated with 2 mL of NaFl becomes unimportant in light of this significant finding regarding image quality."( Evaluation of the side effects and image quality during fluorescein angiography comparing 2 mL and 5 mL sodium fluorescein.
Moosbrugger, KA; Sheidow, TG, 2008
)
0.59
" All of the MPS had varying time-dependent adverse effects on cell morphology, viability, and proliferation during 20- and 60-min exposures."( Cytotoxicity testing of multipurpose contact lens solutions using monolayer and stratified cultures of human corneal epithelial cells.
Hurst, RK; Konynenbelt, BJ; Lim, MJ; Ubels, JL, 2009
)
0.35
" In contrast, because stratified human corneal-limbal epithelial cultures are resistant to adverse effects of MPS, it is suggested that models that simulate the stratified structure of the corneal epithelium should be used for in vitro toxicologic testing."( Cytotoxicity testing of multipurpose contact lens solutions using monolayer and stratified cultures of human corneal epithelial cells.
Hurst, RK; Konynenbelt, BJ; Lim, MJ; Ubels, JL, 2009
)
0.35
"To estimate the rate of serious and total adverse events attributable to intravenous fluorescein when used for gastrointestinal CLE."( The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract.
Canto, MI; Carr-Locke, D; Coron, E; Filoche, B; Fockens, P; Giovannini, M; Kiesslich, R; Lightdale, CJ; Löhr, M; Meining, A; Miehlke, S; Moreau, J; Pohl, H; Roesch, T; Schmidt, C; Wallace, MB, 2010
)
0.88
" fluorescein for CLE who were actively monitored for adverse events were included."( The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract.
Canto, MI; Carr-Locke, D; Coron, E; Filoche, B; Fockens, P; Giovannini, M; Kiesslich, R; Lightdale, CJ; Löhr, M; Meining, A; Miehlke, S; Moreau, J; Pohl, H; Roesch, T; Schmidt, C; Wallace, MB, 2010
)
1.57
" No serious adverse events were reported."( The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract.
Canto, MI; Carr-Locke, D; Coron, E; Filoche, B; Fockens, P; Giovannini, M; Kiesslich, R; Lightdale, CJ; Löhr, M; Meining, A; Miehlke, S; Moreau, J; Pohl, H; Roesch, T; Schmidt, C; Wallace, MB, 2010
)
0.66
"Use of intravenous fluorescein for gastrointestinal CLE appears to be safe with few acute complications."( The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract.
Canto, MI; Carr-Locke, D; Coron, E; Filoche, B; Fockens, P; Giovannini, M; Kiesslich, R; Lightdale, CJ; Löhr, M; Meining, A; Miehlke, S; Moreau, J; Pohl, H; Roesch, T; Schmidt, C; Wallace, MB, 2010
)
0.99
" However, fluorophores can be toxic and must be investigated before they can be administered safely to patients."( Toxicity of organic fluorophores used in molecular imaging: literature review.
Alford, R; Choyke, PL; Duberman, J; Hill, GC; Kobayashi, H; Ogawa, M; Regino, C; Simpson, HM, 2009
)
0.35
" Avoiding injuries to the semicircular canals (SCCs) and facial canal is mandatory, and there is need to find a way to recognize the facial nerve and SCCs for safe performance of mastoidectomy."( Utilization of fluorescein for identification and preservation of the facial nerve and semicircular canals for safe mastoidectomy: a proof of concept laboratory cadaveric study.
Al-Mefty, O; Gragnaniello, C; Kamel, M, 2010
)
0.71
" The fluorescence guides the drilling displaying air cells that are safe to remove."( Utilization of fluorescein for identification and preservation of the facial nerve and semicircular canals for safe mastoidectomy: a proof of concept laboratory cadaveric study.
Al-Mefty, O; Gragnaniello, C; Kamel, M, 2010
)
0.71
" The result of this investigation showed that three types of events caused the risk of toxic exposure: 1 ."( [Safety evaluation of new anticancer chemotherapy administration system: compared to the results from a former study-].
Nakajima, Y; Okajima, H; Terui, K, 2011
)
0.37
" One patient discontinued in the azithromycin group, and five patients discontinued in the rewetting drops group because of adverse events."( Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye.
Bickle, KM; Haque, RM; Nichols, JJ; Nichols, KK; Schiewe, MD; Zink, RC, 2012
)
0.38
" Key outcome measures assessed included: mean change in best-corrected visual acuity (BCVA) from baseline to months 4 (primary endpoint) and 12 (secondary endpoint); other secondary endpoints comprising categorized mean change in BCVA from baseline at month 4 and month 12, mean change in BCVA from baseline at month 4 and month 12 per baseline characteristics; and incidence of ocular and non-ocular adverse events and serious adverse events (SAEs) at month 12."( EXTEND III: efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD.
Chung, H; Kwon, OW; Lai, CC; Lee, FL; Sheu, SJ; Yoon, YH, 2012
)
0.38
"Oral FA proved to be a safe and an adequate technique to evaluate ME."( Safety and efficacy of oral fluorescein angiography in detecting macular edema in comparison with spectral-domain optical coherence tomography.
Azen, S; Barteselli, G; Bartsch, DU; Cheng, L; Chhablani, J; El Emam, S; Freeman, WR; Kozak, I; Lee, SN; Wang, H, 2013
)
0.68
" Data evaluation was based on endpoints including Schirmer test, tear film break-up time, ocular surface staining score, subjective symptom score, and adverse events."( Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials.
Chen, WQ; Li, R; Wang, Y; Wu, D, 2015
)
0.42
"Topical diquafosol seems to be a safe therapeutic option for the treatment of dry eye."( Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials.
Chen, WQ; Li, R; Wang, Y; Wu, D, 2015
)
0.42
" Safety measures included adverse events, slit lamp biomicroscopy, tonometry, blood pressure, and heart rate."( Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
Alekseev, VN; Andryukhina, OM; Bezditko, PA; Brzheskiy, VV; Efimova, EL; Egorov, EA; Fedorkin, ON; Gusarevich, OG; Kamenskikh, TG; Karger, EM; Korol, AR; Lebedev, OI; Miljudin, ES; Mironov, AN; Muzhychuk, OP; Nasinnyk, IO; Ostapenko, V; Popeko, NA; Ryabtseva, AA; Savchenko, AY; Shaidurova, KN; Skulachev, MV; Skulachev, VP; Sumarokova, ES; Surov, AV; Vorontsova, TN; Vygodin, VA; Yani, EV, 2015
)
0.42
"Based on the results of this study, Visomitin is effective and safe for use in eye patients with DES for protection from corneal damage."( Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
Alekseev, VN; Andryukhina, OM; Bezditko, PA; Brzheskiy, VV; Efimova, EL; Egorov, EA; Fedorkin, ON; Gusarevich, OG; Kamenskikh, TG; Karger, EM; Korol, AR; Lebedev, OI; Miljudin, ES; Mironov, AN; Muzhychuk, OP; Nasinnyk, IO; Ostapenko, V; Popeko, NA; Ryabtseva, AA; Savchenko, AY; Shaidurova, KN; Skulachev, MV; Skulachev, VP; Sumarokova, ES; Surov, AV; Vorontsova, TN; Vygodin, VA; Yani, EV, 2015
)
0.42
"Eye drops of 3% diquafosol may be an effective and safe treatment for the management of cataract surgery-induced dry eye aggravation in patients with preexisting dry eye."( Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
Chung, JK; Lee, SJ; Park, DH; Seo, DR, 2016
)
0.43
" Subjects were exposed to a controlled adverse environment chamber at 3 of the 4 study visits (Day -7, Day 1, and Day 29)."( SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model.
Ousler, G; Perekhvatova, N; Petrov, A; Skulachev, M; Stein, L, 2016
)
0.43
"SkQ1 was safe and efficacious in treating dry eye signs and symptoms."( SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model.
Ousler, G; Perekhvatova, N; Petrov, A; Skulachev, M; Stein, L, 2016
)
0.43
"This Phase 2 study indicated that SkQ1 is safe and efficacious for the treatment of dry eye signs and symptoms and supported previous study results."( SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model.
Ousler, G; Perekhvatova, N; Petrov, A; Skulachev, M; Stein, L, 2016
)
0.43
" The present study suggested that 1% D-3-hydroxybutyrate eye drops are safe and effective in treating ocular surface disorders in patients with tear-deficient dry eye disease."( Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease.
Arai, H; Fukagawa, K; Hata, S; Kawakita, T; Okano, T; Sakatani, K; Shimazaki, S; Tanaka, M; Toda, I; Tsubota, K; Uchino, M; Yoshino, K, 2016
)
0.43
" The anaesthesiologists usually perform the puncture, therefore it is necessary to review this method and to specify some anaesthetic considerations such as correct dosing, safe management protocols and medical-legal aspects."( Safe intrathecal fluorescein use for identification of cerebrospinal fluid leaks: Case-report and perioperative algorithm description.
Alcaraz, AB; Benítez, M; Díaz-Alejo, C; González-Pérez, P; Padilla-Del Rey, ML; Rodríguez-Navarro, MÁ, 2017
)
0.79
" The most common treatment-related treatment-emergent adverse event was instillation site pain (7."( One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Amrane, M; Baudouin, C; de la Maza, MS; Figueiredo, FC; Garrigue, JS; Ismail, D; Leonardi, A, 2017
)
0.46
" The numbers of ocular adverse events were low in all treatment groups."( A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Beckert, M; Ciolino, JB; Jentsch, G; Krösser, S; Lonsdale, JD; Moreira, HR; Ousler, GW; Steven, P; Torkildsen, GL; Wirta, DL, 2019
)
0.51
"Maximal safe resection is the goal of modern surgical treatment of high-grade gliomas (HGGs) located close to the motor cortex (M1) and/or the corticospinal tract (CST)."( Surgery of malignant motor-eloquent gliomas guided by sodium-fluorescein and navigated transcranial magnetic stimulation: a novel technique to increase the maximal safe resection.
Angileri, FF; Cardali, SM; Conti, A; Esposito, F; Germanò, A; Picht, T; Raffa, G; Vajkoczy, P; Youssef, M, 2019
)
0.76
" Post-operative acute kidney injury (AKI) occurrence as well as systemic adverse reactions were reported and further compared with 80 matched controls where FL-VA was not used."( Intra-operative fluorescein videoangiography-related nephrotoxicity in intracranial aneurysm surgery: Single center, observational cohort study.
Komuński, P; Świątnicki, W; Szymańska, A; Szymański, J; Urbaniak, F, 2021
)
0.97
"Many studies have demonstrated IF to be safe at low doses (<50mg) with a high sensitivity, specificity and positive predicative value."( The Effectiveness and Safety of Intrathecal Fluorescein in the Management of Cerebrospinal Fluid Leaks.
Ahmed, SK; Banota, A; Gupta, KK; Jolly, K, 2021
)
0.88
"Overall, AR HDFT-F-assisted surgery is safe and effective in maximizing the EOR and PFS rate for patients with newly diagnosed supratentorial HGGs, and in optimizing patient functional outcomes."( Supratentorial high-grade gliomas: maximal safe anatomical resection guided by augmented reality high-definition fiber tractography and fluorescein.
Galzio, R; Giotta Lucifero, A; Lafe, E; Luzzi, S; Maestro, MD; Martinelli, A; Preda, L; Savioli, G; Simoncelli, A, 2021
)
0.82
" Doses <50mg have consistently been shown to be safe while still maintaining effective localisation rates."( The efficacy and safety of intrathecal fluorescein in endoscopic cerebrospinal fluid leak repair -a systematic review.
Ahmed, SK; Gupta, KK; Jolly, K; Muzaffar, J, 2022
)
0.99
" The incidence of adverse drug reactions was investigated for safety evaluation."( Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.
Hori, Y; Inai, M; Oka, K, 2022
)
0.72
" Commonly (incidence ≥ 1%) reported adverse drug reactions in the DE-089C group were eye irritation (3."( Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.
Hori, Y; Inai, M; Oka, K, 2022
)
0.72
" Primary efficacy outcomes were change in the STS from baseline to immediately after treatment administration (visit 1) and change in the EDS from before to 5 minutes after treatment during controlled adverse environment exposure (visit 2)."( Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial.
Jerkins, G; Nau, J; Pattar, GR; Striffler, K; Torkildsen, GL, 2022
)
0.72
" OC-02 SNS was well tolerated: only 2 ocular adverse events were reported (eye pruritis and keratitis), and the most common nonocular events were cough and throat irritation."( Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial.
Jerkins, G; Nau, J; Pattar, GR; Striffler, K; Torkildsen, GL, 2022
)
0.72
"The only side effect was dysgeusia (10% patients)."( Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre.
Jain, K; Jaju, M; Yadav, D, 2023
)
0.91

Pharmacokinetics

Fluorescein is mainly eliminated posteriorly across blood-retina barrier, but FD-150 is cleared via aqueous humour outflow. For intravenously administered fluorscein mean Cmax was 10.

ExcerptReferenceRelevance
" For intravenously administered fluorescein mean Cmax was 10."( Studies on the pharmacokinetics of fluorescein and its dilaurate ester under the conditions of the fluorescein dilaurate test.
Barry, RE; Behrendt, WA, 1985
)
0.83
" The compound showed a pharmacokinetic pattern similar to that of heparin and the plasmatic levels were linearly correlated with anti-factor Xa activity and logarithmically with lipoprotein lipase activation."( Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats.
Barbanti, M; Cristofori, M; Mastacchi, R; Sarret, M, 1985
)
0.54
" The plasma pharmacokinetic data were found to follow a biexponential decay in time."( Plasma pharmacokinetics and interstitial diffusion of macromolecules in a capillary bed.
Jain, RK; Nugent, LJ, 1984
)
0.27
" Data were analyzed by noncompartmental methods (WinNonlin software) and by compartmental population pharmacokinetic methods (NONMEM software)."( Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops.
Abduljalil, K; Diestelhorst, M; Dinslage, S; Doroshyenko, O; Fuhr, U; Lux, A; Steinfeld, A; Süverkrüp, R, 2008
)
0.62
" There is a clear pharmacokinetic advantage of the lyophilisate preparation."( Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops.
Abduljalil, K; Diestelhorst, M; Dinslage, S; Doroshyenko, O; Fuhr, U; Lux, A; Steinfeld, A; Süverkrüp, R, 2008
)
0.62
"The pharmacokinetic study of fluorescein determined the optimum time interval for diagnostic scanning (5-10 min."( Pharmacokinetics and organ distribution of fluorescein in experimental pigs: an input study for confocal laser endomicroscopy of the gastrointestinal tract.
Bures, J; Kopacova, M; Kunes, M; Kvetina, J; Malakova, J; Rejchrt, S, 2010
)
0.91
" Intravitreal concentrations of the compounds were determined and pharmacokinetic parameters were calculated."( Pharmacokinetics of intravitreal macromolecules: Scaling between rats and rabbits.
Puranen, J; Ranta, VP; Ruponen, M; Sadeghi, A; Subrizi, A; Toropainen, E; Urtti, A; Valtari, A, 2021
)
0.62
" Based on pharmacokinetic modelling and compound concentrations in the vitreous and anterior chamber, fluorescein is mainly eliminated posteriorly across blood-retina barrier, but FD-150 is cleared via aqueous humour outflow."( Quantitative intravitreal pharmacokinetics in mouse as a step towards inter-species translation.
Puranen, J; Ranta, VP; Ruponen, M; Sadeghi, A; Urtti, A, 2023
)
1.13

Compound-Compound Interactions

ExcerptReferenceRelevance
"Short-term and long-term results with HR + AC indicated that patients with severe CLI and very poor prognosis benefited in terms of survival and limb salvage from initial therapy with HR infusion combined with long-term oral anticoagulation."( Intravenous hydroxyethylrutosides combined with long-term oral anticoagulation in atherosclerotic nonreconstructable critical leg ischemia: a retrospective study.
Glenne, PO; Inácio, J; Larsson, UB; Lavstedt, S; Lund, F; Qian, Z; Schiötz, J; Tillgren, C, 1999
)
0.3
" Thus, drug-drug interactions involving transporters can often directly affect the therapeutic safety and efficacy of many drugs."( Food-drug interaction between ferulic acid and nateglinide involving the fluorescein/H+ cotransport system.
Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Kobayashi, Y; Kubo, S; Otsuka, Y, 2005
)
0.56
" These results indicate that PAMPA combined with the MultiScreen Caco-2 cell culture may be a useful high throughput screening for predicting passive diffusion and active transport of new drugs."( Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates.
Borremans, C; Brewster, ME; Mackie, C; Masungi, C; Mensch, J; Noppe, M; Van Dijck, A; Willems, B, 2008
)
0.35
"To evaluate the use of autologous solid platelet-rich plasma in combination with an autologous fibrin membrane as a surgical alternative for wound closure in perforated corneal ulcers."( Autologous fibrin membrane combined with solid platelet-rich plasma in the management of perforated corneal ulcers: a pilot study.
Alio, JL; Martinez, LM; Rio, AL; Rodriguez, AE, 2013
)
0.39
"To evaluate the efficacy and safety of autologous serum (AS) eye drops combined with punctal plugs (PPs) in patients with Sjögren syndrome (SS)-related dry eye."( Effectiveness of Autologous Serum Eye Drops Combined With Punctal Plugs for the Treatment of Sjögren Syndrome-Related Dry Eye.
Connell, S; Cui, X; Hirayama, M; Kawakita, T; Liu, Y; Tsubota, K, 2015
)
0.42
" When combined with PPs, the tBUT and RB staining scores were found to be significantly improved in the AS + PP group compared with those of the AS only group."( Effectiveness of Autologous Serum Eye Drops Combined With Punctal Plugs for the Treatment of Sjögren Syndrome-Related Dry Eye.
Connell, S; Cui, X; Hirayama, M; Kawakita, T; Liu, Y; Tsubota, K, 2015
)
0.42
" Furthermore, PPs in combination with AS eye drops were considered to have an additive effect on SS dry eye."( Effectiveness of Autologous Serum Eye Drops Combined With Punctal Plugs for the Treatment of Sjögren Syndrome-Related Dry Eye.
Connell, S; Cui, X; Hirayama, M; Kawakita, T; Liu, Y; Tsubota, K, 2015
)
0.42
"To achieve highly sensitive analysis without labor-intensive experimental procedures in capillary electrophoresis (CE), large-volume sample stacking with an electroosmotic flow pump (LVSEP)-field-amplified sample injection (FASI) was combined with a dynamic coating technique."( Highly Sensitive Analysis in Capillary Electrophoresis Using Large-volume Sample Stacking with an Electroosmotic Flow Pump Combined with Field-amplified Sample Injection.
Kitagawa, F; Nukatsuka, I; Takegawa, Y; Wakagi, S, 2019
)
0.51
" The efficacy of Indocyanine green (ICG) combined with methylene blue (group A) and fluorescein combined with methylene blue (group B) in SLNB of breast cancer was compared, complications were observed at the same time."( Application of fluorescein combined with methylene blue in sentinel lymph node biopsy of breast cancer.
Chu, J; Ding, Y; Gao, N; Li, L; Lin, XN; Liu, JQ; Xu, WH; Yang, AQ, 2021
)
1.2
"To evaluate ocular surface status and corneal higher-order aberrations after a new ocular nebulization therapy combined with meibomian gland massage for the treatment of meibomian gland dysfunction (MGD)."( An investigation into the effects of ocular nebulization combined with meibomian gland massage on ocular surface status and corneal higher-order aberrations for the treatment of meibomian gland dysfunction.
Lin, F; Liu, H; Ma, L; Mao, X, 2022
)
0.72
"In terms of comfort and visual quality, nebulization therapy combined with meibomian gland massage to deliver azithromycin solution and esculin and digitalis glycoside eye drops appears to be more effective in treating clinical symptoms and signs of MGD than simply applying esculin and digitalis glycoside eye drops."( An investigation into the effects of ocular nebulization combined with meibomian gland massage on ocular surface status and corneal higher-order aberrations for the treatment of meibomian gland dysfunction.
Lin, F; Liu, H; Ma, L; Mao, X, 2022
)
0.72
"The aim of the study is to evaluate the safety and effectiveness of amniotic membrane transplantation combined with the closure of the tenon capsule and bulbar conjunctival space."( Efficacy and Safety of Amniotic Membrane Transplantation Combined with Closure of Tenon Capsule and Bulbar Conjunctival Space in the Treatment of Primary Pterygium.
Chen, J; Xu, Y; Zhang, W; Zhao, Z; Zheng, Y, 2022
)
0.72
"This study retrospectively included 100 patients with primary pterygium who received closed bulbar conjunctiva and tenon capsule space combined with amniotic membrane transplantation in our hospital from January 2020 to June 2021 as the experimental group and 100 patients with routine treatment in the same period as the control group."( Efficacy and Safety of Amniotic Membrane Transplantation Combined with Closure of Tenon Capsule and Bulbar Conjunctival Space in the Treatment of Primary Pterygium.
Chen, J; Xu, Y; Zhang, W; Zhao, Z; Zheng, Y, 2022
)
0.72
"Amniotic membrane transplantation combined with the closure of the tenon capsule and bulbar conjunctival space is safer than conventional surgery in the treatment of primary pterygium."( Efficacy and Safety of Amniotic Membrane Transplantation Combined with Closure of Tenon Capsule and Bulbar Conjunctival Space in the Treatment of Primary Pterygium.
Chen, J; Xu, Y; Zhang, W; Zhao, Z; Zheng, Y, 2022
)
0.72

Bioavailability

Fluoresceinsodium was selected as model drug to evaluate and optimize the bioavailability of PNI on rabbits. The mean fluorescein bioavailability from the lyophilisate was up to 11 times higher in the cornea and up to 8.49 ng/ml h. Measurement of the effects of phenolic acids on fluorscein transport across Caco-2 monolayers would be a usef

ExcerptReferenceRelevance
" The use of absorbable intracanalicular collagen implants may increase the bioavailability of topically applied ocular solutions."( Effect of intracanalicular collagen implants on the absorption of topically applied sodium fluorescein.
Hill, JH; Kaufman, HE; Reidy, JJ; Unterman, SR, 1991
)
0.5
" Bioavailability of fluorescein by oral administration was 99%."( Studies on the pharmacokinetics of fluorescein and its dilaurate ester under the conditions of the fluorescein dilaurate test.
Barry, RE; Behrendt, WA, 1985
)
0.87
" The affinity of PLA particles for intestinal epithelia and GALT needs to be greatly enhanced in order to achieve improved oral bioavailability of macromolecules."( Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia.
Brayden, D; Clarke, N; McClean, S; Meehan, E; O'Malley, D; Prosser, E; Ramtoola, Z, 1998
)
0.3
" Limited oral bioavailability or excessive production costs have prevented these inhibitors from becoming new antihypertensive drugs."( Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?
Binggeli, A; Breu, V; Bur, D; Clozel, JP; D'Arcy, A; Dorn, A; Fischli, W; Grüninger, F; Güller, R; Hirth, G; M ller, M; Märki, H; Mathews, S; Oefner, C; Ridley, RG; Stadler, H; Vieira, E; Wilhelm, M; Winkler, F; Wostl, W, 1999
)
0.3
"A positively charged self-emulsifying oil formulation (SEOF), aimed to enhance oral bioavailability of drugs poorly soluble in water, was recently developed."( Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity.
Benita, S; Gershanik, T; Haltner, E; Lehr, CM, 2000
)
0.31
"0% bioavailability by virtue of HPC increasing the dissolution and retarding the mucociliary clearance."( Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres.
Kinoshita, W; Makino, Y; Sakagami, M; Sakon, K, 2001
)
0.31
"To assess the ocular bioavailability of fluorescein from a novel water free, freeze dried ophthalmic drug delivery system compared to conventional preservative-free fluorescein eye drops."( Lyophilisates for drug delivery in ophthalmology: pharmacokinetics of fluorescein in the human anterior segment.
Diestelhorst, M; Dinslage, S; Süverkrüp, R; Weichselbaum, A, 2002
)
0.82
"The greater intraocular bioavailability of fluorescein from the lyophilisate relative to the solution suggests that it may be a useful method for delivering substances to the eye."( Lyophilisates for drug delivery in ophthalmology: pharmacokinetics of fluorescein in the human anterior segment.
Diestelhorst, M; Dinslage, S; Süverkrüp, R; Weichselbaum, A, 2002
)
0.81
" Measurement of the effects of phenolic acids on fluorescein transport across Caco-2 monolayers would be a useful way to evaluate the intestinal absorption or bioavailability of dietary phenolic acids."( Transepithelial transport of fluorescein in Caco-2 cell monolayers and use of such transport in in vitro evaluation of phenolic acid availability.
Hagiwara, K; Konishi, Y; Shimizu, M, 2002
)
0.86
"To study the ocular bioavailability of a triple dose, single application of sodium fluorescein to the human anterior segment from a novel drug delivery device."( A comparative bioavailability study of three conventional eye drops versus a single lyophilisate.
Diestelhorst, M; Dinslage, S; Lux, A; Maier, S; Süverkrüp, R, 2003
)
0.54
" A significantly better bioavailability was achieved in the cornea and anterior chamber for up to 7 hours by means of drug application with lyophilisates."( A comparative bioavailability study of three conventional eye drops versus a single lyophilisate.
Diestelhorst, M; Dinslage, S; Lux, A; Maier, S; Süverkrüp, R, 2003
)
0.32
"49 ng/ml h and finally, the absolute bioavailability (F%) of the "lung-region-specific" deposition and absorption of fluorescein was estimated to be 55."( Fractional contribution of lung, nasal and gastrointestinal absorption to the systemic level following nose-only aerosol exposure in rats: a case study of 3.7- micro m fluorescein aerosols.
Kinoshita, W; Makino, Y; Sakagami, M; Sakon, K, 2003
)
0.72
"To assess the ocular bioavailability of fluorescein from a novel drug delivery system compared with one single preservative free eye drop."( Bioavailability of fluorescein from a new drug delivery system in human eyes.
Diestelhorst, M; Lux, A; Maier, S; Steinfeld, A; Süverkrüp, R, 2004
)
0.92
"A significantly better bioavailability was achieved in human eyes by using lyophilisate compared with the same dose from a conventional eye drop."( Bioavailability of fluorescein from a new drug delivery system in human eyes.
Diestelhorst, M; Lux, A; Maier, S; Steinfeld, A; Süverkrüp, R, 2004
)
0.65
" Pharmacokinetic modelling showed a significantly higher absorption rate and lower T(max) in the ipsilateral striatum (0."( The potential of nasal application for delivery to the central brain-a microdialysis study of fluorescein in rats.
Bagger, MA; Bechgaard, E, 2004
)
0.54
" Numerous studies have addressed the mechanism of uptake and kinetics of TAT translocation, but the cytosolic concentrations and bioavailability of the transported cargo have not been well-characterized."( Characterization of TAT-mediated transport of detachable kinase substrates.
Allbritton, NL; Cheung, SH; Li, H; Rossi, FM; Sims, CE; Soughayer, JS; Stanbridge, EJ; Wang, Y, 2004
)
0.32
" Therefore, these findings indicated that the viscous vehicles were effective to regulate the absorption rate of CF."( Control of pulmonary absorption of water-soluble compounds by various viscous vehicles.
Fujita, T; Muramatsu, H; Muranishi, S; Nishinaka, A; Okada, N; Okumura, S; Yamada, K; Yamamoto, A, 2004
)
0.32
" In this study, fluoresceinsodium was selected as model drug to evaluate and optimize the bioavailability of PNI on rabbits."( [Bioavailability and influncing factors of self-designed powder needleless injection system on rabbits].
Jin, C; Li, W; Wang, JB; Xiao, XH; Zhou, X, 2007
)
0.69
"The objective of this evaluation was to model ocular pharmacokinetics of fluorescein administered as conventional eye drops and as lyophilisate to healthy volunteers in order to assess the relative bioavailability of the lyophilisate formulation."( Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops.
Abduljalil, K; Diestelhorst, M; Dinslage, S; Doroshyenko, O; Fuhr, U; Lux, A; Steinfeld, A; Süverkrüp, R, 2008
)
0.85
"The data clearly show a considerably superior intraocular bioavailability of fluorescein when given as lyophilisate compared to conventional eye drops."( Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops.
Abduljalil, K; Diestelhorst, M; Dinslage, S; Doroshyenko, O; Fuhr, U; Lux, A; Steinfeld, A; Süverkrüp, R, 2008
)
0.85
" Therefore, the present study aims to investigate the effects of genistein, a potent phyto-antioxidant, and exercise training on age-induced endothelial dysfunction in relation to NO bioavailability using in situ NO-sensitive fluorescent dye detection."( Increased NO bioavailability in aging male rats by genistein and exercise training: using 4, 5-diaminofluorescein diacetate.
Eksakulkla, S; Patumraj, S; Siriviriyakul, P; Suksom, D, 2009
)
0.57
" Moreover, this feature is intended to be used to analyze formulation approaches aiming for an improved oral drug bioavailability by application of excipients that increase the paracellular permeability of the intestinal epithelial barrier."( Online monitoring of transepithelial electrical resistance (TEER) in an apparatus for combined dissolution and permeation testing.
Balbach, S; Eichinger, T; Koenig, P; Lehr, CM; Loos, P; Muendoerfer, M; Schaefer, UF; Walk, JS, 2010
)
0.36
" Bioavailability studies were carried out in Sprague Dawley rats with various formulations."( Thiolated polycarbophil/glutathione: defining its potential as a permeation enhancer for oral drug administration in comparison to sodium caprate.
Barthelmes, J; Bernkop-Schnürch, A; Bonn, GK; Krieg, C; Perera, G; Uhlschmied, C; Vetter, A, 2011
)
0.37
" By decreasing particle sizes nanosuspensions enhance dissolution rate and bioavailability of the active pharmaceutical ingredient."( Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics.
Geissler, S; Hill, A; Mäder, K; Weigandt, M, 2012
)
0.38
" The aim of this study to assess the bioavailability and safety of SFAs as drug solvents for the topical ocular application of Cyclosporin A (CsA)."( Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
Dutescu, RM; Merkel, OM; Panfil, C; Schrage, N, 2014
)
0.4
" DFO antioxidant and iron binding properties were preserved and its bioavailability was increased upon CPP conjugation, which opens new therapeutic possibilities for neurodegenerative processes associated with brain iron overload."( Cell penetrating peptide (CPP)-conjugated desferrioxamine for enhanced neuroprotection: synthesis and in vitro evaluation.
Esposito, BP; Goswami, D; Machini, MT; Nomura, CS; Silvestre, DM, 2014
)
0.4
" Therefore, no definitive conclusions on relative bioavailability can be drawn from this experiment."( A New Spray Device to Deliver Topical Ocular Medication: Penetration of Fluorescein to the Anterior Segment.
de Kruijf, WP; van Rooij, J; Wubbels, RJ, 2015
)
0.65
" Dysfunctional eNOS such as uncoupling of eNOS leads to decrease in NO bioavailability and increase in superoxide anion (O2(."( En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries.
Ming, XF; Montani, JP; Xiong, Y; Yang, Z; Yu, Y, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, drug bioavailability via the oral route remains poor due to the harsh gastrointestinal environment."( Fluorescein Isothiocyanate Chitosan Nanoparticles in Oral Drug Delivery Studies.
Calabrese, G; Caprifico, AE; Foot, PJS; Polycarpou, E, 2020
)
2
"Insufficient solubility and stability of bioactive small molecules as well as poor biocompatibility may cause low bioavailability and are common obstacles in drug development."( Drug delivery of 6-bromoindirubin-3'-glycerol-oxime ether employing poly(D,L-lactide-co-glycolide)-based nanoencapsulation techniques with sustainable solvents.
Bachmann, V; Czapka, A; Dirauf, M; Fischer, D; Grune, C; Jandt, KD; Schädel, P; Scheuer, K; Schubert, US; Skaltsounis, AL; Weber, C; Werz, O, 2022
)
0.72
"Our formulation method of PLGA-based nanoparticles by applying sustainable, non-toxic solvents is a feasible nanotechnology that circumvents the poor bioavailability and biocompatibility of the cargo 6BIGOE."( Drug delivery of 6-bromoindirubin-3'-glycerol-oxime ether employing poly(D,L-lactide-co-glycolide)-based nanoencapsulation techniques with sustainable solvents.
Bachmann, V; Czapka, A; Dirauf, M; Fischer, D; Grune, C; Jandt, KD; Schädel, P; Scheuer, K; Schubert, US; Skaltsounis, AL; Weber, C; Werz, O, 2022
)
0.72
" The drug of choice Cyclosporine A (CsA) exhibits poor ocular bioavailability due to high molecular weight and lipophilicity."( Oil-free eye drops containing Cyclosporine A/cyclodextrin/PVA supramolecular complex as a treatment modality for dry eye disease.
Birangal, S; Chaudhari, P; Ghate, V; Kodoth, AK; Lewis, SA; Mallela, LS; Mavlankar, N; Nampoothiri, M; Pal, A; Roy, S, 2022
)
0.72

Dosage Studied

Fluorescein-labelled sulodexide tissue distribution was studied in the rat after intravenous administration at the dosage of 15 mg/kg. Each intra-abdominal organ was clearly observed with the same imaging quality we obtained in mice model.

ExcerptRelevanceReference
"105 patients were orally given fluorescein of different dosage and concentration for fundus angiography."( [The effect of dosage on oral fluorescein angiography of the fundus].
Li, RX; Zhang, SL, 1992
)
0.86
" Fundus fluorescence under slitlamp illumination was poor for patients receiving the lower dosage of fluorescein, whereas at the higher dosage it was visible in all but one patient."( Oral fluorescein angiography and fluoroscopy: determination of plasma fluorescein levels and clinical application.
Gómez-Ulla, F; Malvar, A; Parafita, M; Polo, P; Seoane, I, 1992
)
1.01
"The motility of bile canaliculi was examined in hepatocyte couplets permeabilized with palmitoyl lysophosphatidyl choline in a dosage regimen that drastically affected secretory function, yet maintained relative integrity of the cellular cytoskeleton."( Permeabilized hepatocyte couplets. Adenosine triphosphate-dependent bile canalicular contractions and a circumferential pericanalicular microfilament belt demonstrated.
Edwards, V; Phillips, MJ; Smith, CR; Tsukada, N; Watanabe, N, 1991
)
0.28
" In the third study, the corneal permeability to fluorescein was determined in 10 subjects after dosing with 50 ppm H2O2, 500 ppm H2O2, as well as negative and positive controls."( Clinical aspects of topical application of dilute hydrogen peroxide solutions.
McNally, JJ,
)
0.39
"97) was observed between the dose of administered goat 125I-IgG and the amount bound to isolated glomeruli over the entire dosage range."( Quantitation of antigen in tissue by immunofluorescence image analysis.
Basgen, JM; Michael, AF; Nevins, TE, 1989
)
0.28
"Fluorescein-labelled sulodexide tissue distribution was studied in the rat after intravenous administration at the dosage of 15 mg/kg."( Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II: Organ distribution in rats.
Franchi, M; Guizzardi, S; Mastacchi, R; Morocutti, M; Ruggeri, A, 1985
)
1.98
" The dose-response curves for parameters were powers with negative exponent indicating considerable saturation of the F-GAG elimination process."( Pharmacokinetics of fluorescein-labelled glycosaminoglycans and of their lipoprotein lipase-inducing activity in the rat.
Madonna, M; Pescador, R, 1982
)
0.59
"A peroral dosage form was examined to deliver recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the colon in beagle dogs."( Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs.
Ikeda, C; Imagawa, N; Niwa, K; Takada, K; Takaya, T, 1995
)
0.29
" Like all GPIIb/IIIa antagonists, DMP 728 has a steep dose-response relationship in inhibiting platelet aggregation."( Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic Arg-Gly-Asp peptide.
Bozarth, JM; Flint, SK; Forsythe, MS; Jackson, SA; Mousa, SA; Tsao, PW, 1995
)
0.53
" This dosage schedule will maintain a relatively constant level of corticosteroid action throughout a 24-hour period."( The effect of oral dexamethasone on the circadian rhythm of aqueous humor flow in humans.
Brubaker, RF; Larsson, LI; Rettig, ES; Sheridan, PT; Young, WF, 1994
)
0.29
" The routine assay for characterizing a specific photosensitizer at a standard dose consists of the sequential allocation of eight mice to a set of different light doses designed to span the dose-response range of fluorescein fluorescence exclusion (measured 8-10 min after fluorescein injection)."( The validation of a new vascular damage assay for photodynamic therapy agents.
Bellnier, DA; Greco, WR; Henderson, BW; Johnson, P; Parsons, JC; Potter, WR; Sitnik, TM; Vaughan, LA; Whitaker, J, 1995
)
0.48
" The present study determined the time course and the dose-response relationship of radiation-induced hyperpermeability in cultured bovine pulmonary artery endothelial (BPAE) cells."( Dose-response effects of radiation on the permeability of endothelial cells in culture.
Molteni, A; Taylor, JM; Ward, WF; Waters, CM, 1996
)
0.29
" The dose-response curve of IL-1 alpha-induced uveitis was inhibited in a non-competitive manner."( Tetrandrine inhibits breakdown of blood-aqueous barrier induced by endotoxin and interleukin-1 alpha in rats.
Chiou, GC; Xiao, JG, 1996
)
0.29
" Recommendations on the correct dosage of intrathecal fluorescein for diagnosis of cerebrospinal fluid fistulae are proposed."( Cerebrospinal fluid fistulae in a canine model.
Massey, SO; Murphy, TP; Syms, CA; Syms, MJ, 1997
)
0.55
" The degree of difference, whilst achieving statistical significance, should not affect insulin dosage clinically."( The effect of fluorescein on the accuracy of blood glucose determination by glucose meters.
Antcliff, RJ; Hugkulstone, CE, 1999
)
0.66
" Mast-cell tryptase was dosed in serum and a pulmonary immunohistochemical evaluation was performed."( Fatal anaphylactic shock during a fluorescein angiography.
Fineschi, V; Monasterolo, G; Rosi, R; Turillazzi, E, 1999
)
0.58
"To evaluate the safety and short-term visual and fluorescein angiographic effects of a single photodynamic therapy treatment with verteporfin with the use of different dosage regimens in patients with choroidal neovascularization (CNV) from age-related macular degeneration."( Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
Barbazetto, I; Birngruber, R; Bressler, NM; Donati, G; Fsadni, M; Gragoudas, ES; Gray, T; Lane, AM; Laqua, H; Manjuris, U; Miller, JW; Piguet, B; Pournaras, CJ; Schmidt-Erfurth, U; Sickenberg, M; Strong, A; van den Berg, H; Zografos, L, 1999
)
0.56
"Nonrandomized, multicenter, open-label, clinical trial using 5 dosage regimens."( Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
Barbazetto, I; Birngruber, R; Bressler, NM; Donati, G; Fsadni, M; Gragoudas, ES; Gray, T; Lane, AM; Laqua, H; Manjuris, U; Miller, JW; Piguet, B; Pournaras, CJ; Schmidt-Erfurth, U; Sickenberg, M; Strong, A; van den Berg, H; Zografos, L, 1999
)
0.3
"Nonrandomized, multicenter, open-label phase 1 and 2 clinical trial using 2 different retreatment dosage regimens."( Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Barbazetto, I; Birngruber, R; Bressler, NM; Donati, G; Fsadni, M; Gragoudas, ES; Gray, T; Lane, AM; Laqua, H; Manjuris, U; Miller, JW; Piguet, B; Pournaras, CJ; Schmidt-Erfurth, U; Sickenberg, M; Strong, HA; van den Berg, H; Zografos, L, 1999
)
0.3
"Three Dimensional Printing is a novel technique used in the fabrication of complex oral dosage delivery pharmaceuticals."( Oral dosage forms fabricated by three dimensional printing.
Cima, MJ; Giritlioglu, B; Katstra, WE; Palazzolo, RD; Rowe, CW; Teung, P, 2000
)
0.31
" However, repeated dosing with endothelin-1 at a 24 hr intervals caused a highly enhanced disruption of blood-brain barrier permeability in dogs, but not in rats, whereas the repeated administration with a 48 hr interval markedly increased the blood-brain barrier permeability in both species of animals (dogs: 923%, rats: more than 661%)."( Highly enhanced permeability of blood-brain barrier induced by repeated administration of endothelin-1 in dogs and rats.
Kita, T; Kubo, K; Momochi, C; Nakashima, T; Narushima, I; Ohno, N; Yonetani, Y; Yoshikawa, I, 2003
)
0.32
"0 mA 2 of 4 subjects reported a burning sensation under the applicator during dosing which resolved by 22 hr post-dose; superficial changes in fluorescein staining were observed at 1 hr, but not at 22 hr."( Tolerance of ocular iontophoresis in healthy volunteers.
Bakhtyari, A; Febbraro, S; Ferguson, E; King, M; Mundasad, M; Parkinson, TM, 2003
)
0.52
"A single centered, active-controlled, three-period crossover comparison that evaluated conjunctival and corneal punctate staining, by grade and individual stains, in healthy subjects after dosing for five days in one eye with latanoprost, bimatoprost, or travoprost."( Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects.
Jackson, AL; Jenkins, JN; Stewart, JA; Stewart, WC, 2003
)
0.32
"33) or at 1 hour after dosing (latanoprost 23."( Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects.
Jackson, AL; Jenkins, JN; Stewart, JA; Stewart, WC, 2003
)
0.32
"A novel microfluidic device was designed and developed to miniaturize, multiplex, and automate serial dilution and three-reagent dose-response assays using submicroliter quantities of reagents."( A prototype microfluidic platform for miniaturization and automation of serial dilution and dose-response assays.
Coyne, C; Flynn, T; Koehler, J; Levine, L; Pezzuto, M; Vajjhala, S; Williams, M, 2002
)
0.31
"7 cells with a high concentration of Staphylococcus aureus (Gram-positive, lysed bacteria), could not generally be detected by the LAL test, but they were found to be reduced, in a dose-response relationship, with this new system."( In vitro bioassay of endotoxin using fluorescein as a pH indicator in a macrophage cell culture system.
Aihara, M; Han, DW; Lee, DH; Lee, MS; Park, JC; Ryu, GH; Sung, HJ; Takatori, K, 2005
)
0.6
" To achieve dry polymer application, a new, experimental dosage form named Eutex (made of Eudragit L100-55 and latex) capsule has been developed."( Comparative in vivo mucoadhesion studies of thiomer formulations using magnetic resonance imaging and fluorescence detection.
Albrecht, K; Bernkop-Schnürch, A; Debbage, P; Greindl, M; Kremser, C; Wolf, C, 2006
)
0.33
" Ocular burning or irritation was noted in 3 patients (19%), which improved with either continuation of cyclosporine at the current dosing regimen or reduction in dose and/or concentration of cyclosporine."( Ophthalmic cyclosporine use in ocular GVHD.
Farjo, QA; Gupta, A; Lelli, GJ; Mian, SI; Musch, DC; Nairus, TM, 2006
)
0.33
" The antioxidant activity of resveratrol was dependent on the complexed resveratrol because CDs acts as a controlled dosage reservoir that protects resveratrol against rapid oxidation by free radicals."( ORAC-fluorescein assay to determine the oxygen radical absorbance capacity of resveratrol complexed in cyclodextrins.
Fortea, MI; Gabaldón, JA; Lucas-Abellán, C; Mercader-Ros, MT; Núñez-Delicado, E; Zafrilla, MP, 2008
)
0.86
"5microM, which is significantly lower than the 2microM dosage concentration."( Quantitating the concentration of Py-Im polyamide-fluorescein conjugates in live cells.
Dervan, PB; Hsu, CF, 2008
)
0.6
" In the human eye sting test, 10 mul of a 10% dosing solution is instilled into one eye of each panelist (n = 20), and the contralateral eye is dosed with sterile water as a control."( Comparison of in vitro eye irritation potential by bovine corneal opacity and permeability (BCOP) assay to erythema scores in human eye sting test of surfactant-based formulations.
Cater, KC; Harbell, JW, 2008
)
0.35
" Collectively, these results show that this potent antiproliferative tubulysin compound can be specifically delivered to FR-positive tumors to provide substantial therapeutic benefit using well-tolerable dosing regimens."( Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Dorton, R; Leamon, CP; Parker, N; Reddy, JA; Vetzel, M; Vlahov, I; Wang, Y; Westrick, E, 2008
)
0.35
" The values of IC(50) and Hill number for the inhibitors were determined from dose-response curves of the quenching inhibition."( Inhibition of anti-fluorescent probe monoclonal antibody by long-chain amphiphiles.
Kaneshina, S; Matsuki, H; Morimitsu, T; Nagamune, H; Nishimoto, M; Tamai, N, 2010
)
0.36
"More accurate dose-response curves can be constructed by eliminating aqueous serial dilution of compounds."( Gradient, contact-free volume transfers minimize compound loss in dose-response experiments.
Datwani, S; Ellson, R; Harris, D; Olechno, J, 2010
)
0.36
" Fluorescein was dosed intravenously and monitored simultaneously online as a marker of in vivo blood-brain barrier permeability."( Development of a PDMS-based microchip electrophoresis device for continuous online in vivo monitoring of microdialysis samples.
Desai, DP; Lunte, SM; Nandi, P, 2010
)
1.27
" This may result in great improvement in consumer compliance, avoid frequent dosing and enhance the therapeutic effectiveness."( Smart polymeric nanofibers for topical delivery of levothyroxine.
Azarbayjani, AF; Chan, SY; Chan, YW; Lim, PF; Ramakrishna, S; Venugopal, JR, 2010
)
0.36
"Simultaneous IA with a rapid localization technique allows high-quality imaging of the pigmented rabbits and the moderate dosage of 5 mg FS and 5 mg ICG is preferred for best visualization."( A simultaneous iris angiography technique in pigmented rabbits.
Lin, S; Liu, AH; Wu, JG; Zhou, XX, 2012
)
0.38
" These findings suggest that dosing of topical medications may need to be increased in eyes with a history of CXL to achieve expected therapeutic effects, and they may have implications for the long-term health of the cornea."( Cross-linking with ultraviolet-a and riboflavin reduces corneal permeability.
Lamy, R; Lee, OT; Schultz, DS; Stewart, JM; Wong, FF, 2011
)
0.37
" Each site was dosed with 3 mL of successively increasing concentrations of fluorescein-labeled saline."( Dose quantification of topical drug delivery to the paranasal sinuses by fluorescein luminosity calculation.
Bleier, BS; Harvey, RJ; Preena, D; Schlosser, RJ,
)
0.59
" Dose-response curves for fluorescein and Texas Red based on USL concentration gradients near the surface of the Malpighian tubule were comparable to those based on collection and analysis of secreted fluid droplets."( Determining rates of epithelial solute transport by optical measurement of fluorochrome concentration gradients in the unstirred layer.
O'Donnell, MJ; Seabrooke, S, 2012
)
0.68
"A randomized, double-masked, multicenter, placebo-controlled, parallel-group, dose-response phase II study."( Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Awamura, S; Kinoshita, S; Nakamichi, N; Oshiden, K; Suzuki, H; Yokoi, N, 2012
)
0.38
" Choroid-retina T(max) was observed immediately after dosing with suprachoroidal injections and at 10 and 27."( Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry.
Kadam, RS; Kompella, UB; Tyagi, P, 2012
)
0.38
" Six healthy, mature, mixed-breed dogs were anesthetized and then dosed intravenously with fluorescein at 15 mg/kg."( The exogenous fluorophore, fluorescein, enables in vivo assessment of the gastrointestinal mucosa via confocal endomicroscopy: optimization of intravenous dosing in the dog model.
Mansfield, CS; Sharman, MJ; Whittem, T, 2013
)
0.91
" As one demonstrative application, we show the suitability of the technique for generating a dose-response curve for an enzyme inhibition assay."( Generation of chemical concentration gradients in mobile droplet arrays via fragmentation of long immiscible diluting plugs.
Sun, M; Vanapalli, SA, 2013
)
0.39
" Second, to determine whether drug distribution differs between the dosed and undosed side of the eye following suprachoroidal delivery."( Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes.
Edelhauser, HF; Kadam, RS; Kompella, UB; Tyagi, P; Williams, J, 2013
)
0.39
" Beta-blockers and FITC-dextrans were localized more to the dosed side when compared to the opposite side of the sclera, choroid-RPE, retina, and vitreous."( Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes.
Edelhauser, HF; Kadam, RS; Kompella, UB; Tyagi, P; Williams, J, 2013
)
0.39
" The study indicates that FF 3DP has the potential to offer a new solution for fabricating personalized-dose medicines or unit dosage forms with controlled-release profiles."( Fused-filament 3D printing (3DP) for fabrication of tablets.
Basit, AW; Buanz, AB; Gaisford, S; Goyanes, A, 2014
)
0.4
" Both showed a dose-response increase with surface stimulation and were correlated with each other."( The Effects of Increasing Ocular Surface Stimulation on Blinking and Tear Secretion.
Begley, CG; Bradley, A; Braun, R; King-Smith, E; Port, N; Wu, Z, 2015
)
0.42
" The dosage of 1 % fluorescein (3 ml/body) was appropriate in observing intra-abdominal organs, and each intra-abdominal organ was clearly observed with the same imaging quality we obtained in mice model."( A novel approach of optical biopsy using probe-based confocal laser endomicroscopy for peritoneal metastasis.
Doki, Y; Hara, H; Higashi, S; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Naka, T; Nakajima, K; Nakatsuka, R; Sumiyama, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2016
)
0.76
" This increased delivery increases the therapeutic index of cisplatin and reduces side effects caused by a high dosage or long-term treatment times."( A new hexapeptide from the leader peptide of rMnSOD enters cells through the oestrogen receptor to deliver therapeutic molecules.
Birolo, L; Bonelli, P; Borrelli, A; Capasso, C; Carpentieri, A; De Luca, V; Gori, E; Mancini, A; Mancini, R; Pica, A; Pollio, ML; Pucci, P; Rommelaere, J; Ruggiero, MG; Sanseverino, M; Schiattarella, A; Tuccillo, FM, 2016
)
0.43
"Image quality can be guaranteed with the conventional dosage of fluorescein sodium in probe-based confocal laser endomicroscopy (pCLE)."( A lower dose of fluorescein sodium is more suitable for confocal laser endomicroscopy: a feasibility study.
Bai, L; Du, JX; Gao, XZ; Ji, R; Li, CQ; Li, YQ; Li, Z; Yin, YF; Zhai, ZZ; Zhang, YL; Zuo, XL, 2016
)
1.02
"To assess (i) the adverse reactions (ARs) associated with intravenous fluorescein angiography (IVFA); (ii) the relationship between a known history of IVFA-associated AR and ARs on the subsequent IVFA test; and (iii) the dose-response relationship between intravenous sodium fluorescein (NaFl) injection and ARs associated with IVFA."( Intravenous fluorescein angiography-associated adverse reactions.
Li, C; Sharma, S; Tzankova, V; Xu, K, 2016
)
1.05
" Among 17 patients who had 2 repeated IVFA tests and an AR on the first IVFA test, the rate of AR on the second test was lower in patients who received a reduced dosage of NaFl (n = 14) compared to those with the standard dosage (n = 3) (35."( Intravenous fluorescein angiography-associated adverse reactions.
Li, C; Sharma, S; Tzankova, V; Xu, K, 2016
)
0.81
"Despite being the most prominent dosage form for topical ocular delivery, eye-drops have several well-recognized drawbacks."( Precision Ocular Drug Delivery Via Aerosol Ring Vortices.
Herpin, MJ; Smyth, HDC, 2017
)
0.46
" The combination of the modified VM and EyeMoS seems a valuable tool for characterizing intravitreal dosage forms in a reproducible simulation of diversified eye movements and a partially liquefied or vitrectomized vitreous body."( Distribution of fluorescein sodium and triamcinolone acetonide in the simulated liquefied and vitrectomized Vitreous Model with simulated eye movements.
Bogdahn, M; Rosenbaum, C; Seidlitz, A; Stein, S; Weitschies, W, 2017
)
0.8
" Dosing and incubation time should be considered carefully for NaFl-based fluorescence-guided surgery (FGS) of glioma."( Elucidating the kinetics of sodium fluorescein for fluorescence-guided surgery of glioma.
Davis, SC; Filan, C; Folaron, M; Roberts, DW; Samkoe, KS; Strawbridge, R, 2018
)
0.76
" 5-ALA was orally administered 3 hours before induction of anesthesia at a dosage of 20 mg/kg, whereas fluorescein was intravenously administered at induction of anesthesia at a dosage of 4 mg/kg."( Combined Fluorescence Using 5-Aminolevulinic Acid and Fluorescein Sodium at Glioblastoma Border: Intraoperative Findings and Histopathologic Data About 3 Newly Diagnosed Consecutive Cases.
Della Puppa, A; Gardiman, MP; Munari, M; Volpin, F, 2019
)
0.98
"After a 2-week run-in period with twice-daily dosing of Systane Balance (Alcon, Fort Worth, TX), patients were randomized to the respective treatment arm and dosed twice daily for 16 weeks."( A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Beckert, M; Ciolino, JB; Jentsch, G; Krösser, S; Lonsdale, JD; Moreira, HR; Ousler, GW; Steven, P; Torkildsen, GL; Wirta, DL, 2019
)
0.51
" By controlling the concentration and dosing schedule of adapter administration, we document two methods that can rapidly terminate (<3 h) a pre-existing CRS-like toxicity and two unrelated methods that can pre-emptively prevent a CRS-like toxicity that would have otherwise occurred."( Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters.
Chu, H; Leamon, CP; Lee, YG; Low, PS; Lu, Y; Putt, KS; Srinivasarao, M, 2019
)
0.51
" SEECASE evaluated the efficacy, safety, and tolerability of NOV03 at 2 dosing regimens compared with a saline comparator in patients with DED."( A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease.
Krösser, S; Majmudar, PA; Sall, K; Tauber, J; Willen, D; Wirta, DL, 2021
)
0.62
" Based on the most common doses used in this group, we recommend utilisation of a dosing below 50mg, with the most frequent range being between 10-30mg."( The efficacy and safety of intrathecal fluorescein in endoscopic cerebrospinal fluid leak repair -a systematic review.
Ahmed, SK; Gupta, KK; Jolly, K; Muzaffar, J, 2022
)
0.99
"The efficacy and safety of DE-089C administered three times daily at half the dosage of DQS in patients with dry eye were confirmed in this study."( Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.
Hori, Y; Inai, M; Oka, K, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
radioopaque mediumA substance having the property of absorbing, and therefore being opaque to, electromagnetic radiation, particularly X-rays.
fluorescent dyenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
xanthene dyeA dye derived by condensation of phthalic anhydride with resorcinol (and derivatives) or m-aminophenol (and derivatives).
gamma-lactoneA lactone having a five-membered lactone ring.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
oxaspiro compoundA spiro compound in which at least one of the cyclic components is an oxygen heterocyle.
2-benzofurans
organic heteropentacyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency29.90330.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.00940.004023.8416100.0000AID485290
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency47.55950.125919.1169125.8920AID2549; AID504841
Chain A, Ferritin light chainEquus caballus (horse)Potency35.48135.623417.292931.6228AID485281
acetylcholinesteraseHomo sapiens (human)Potency0.56380.002541.796015,848.9004AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency43.64653.189029.884159.4836AID1224846
SMAD family member 2Homo sapiens (human)Potency35.59640.173734.304761.8120AID1346859; AID1346924; AID1347035
SMAD family member 3Homo sapiens (human)Potency35.59640.173734.304761.8120AID1346859; AID1346924; AID1347035
Microtubule-associated protein tauHomo sapiens (human)Potency0.63100.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency22.34000.000221.22318,912.5098AID743035; AID743036; AID743040; AID743053; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency54.48270.000657.913322,387.1992AID1259377; AID1259378
progesterone receptorHomo sapiens (human)Potency54.48270.000417.946075.1148AID1346784; AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency30.27980.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency76.95880.003041.611522,387.1992AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency28.21450.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.53780.001530.607315,848.9004AID1224841; AID1224842; AID1259401
farnesoid X nuclear receptorHomo sapiens (human)Potency25.71160.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency21.68990.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.58530.000229.305416,493.5996AID743069; AID743075; AID743078; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency26.10140.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency25.98500.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency17.63000.023723.228263.5986AID743222; AID743223; AID743241
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency21.68990.000723.06741,258.9301AID743085
activating transcription factor 6Homo sapiens (human)Potency41.24340.143427.612159.8106AID1159516; AID1159519
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency0.34550.154917.870243.6557AID1346877; AID1346891
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency48.972219.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency34.09540.057821.109761.2679AID1159526; AID1159528
Bloom syndrome protein isoform 1Homo sapiens (human)Potency28.93420.540617.639296.1227AID2528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency51.05300.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency29.97580.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency25.55730.000627.21521,122.0200AID743202; AID743219
DNA polymerase kappa isoform 1Homo sapiens (human)Potency30.77890.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency29.90330.251215.843239.8107AID504327
Cellular tumor antigen p53Homo sapiens (human)Potency38.18180.002319.595674.0614AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1422649Binding affinity to Escherichia coli SurA at 5 nM by fluorescence anisotropy2018Bioorganic & medicinal chemistry letters, 12-01, Volume: 28, Issue:22
Identification of inhibitors of the E. coli chaperone SurA using in silico and in vitro techniques.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,873)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990828 (14.10)18.7374
1990's1072 (18.25)18.2507
2000's1707 (29.07)29.6817
2010's1738 (29.59)24.3611
2020's528 (8.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.18 (24.57)
Research Supply Index8.78 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index134.40 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (73.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials283 (4.55%)5.53%
Reviews148 (2.38%)6.00%
Case Studies224 (3.60%)4.05%
Observational30 (0.48%)0.25%
Other5,529 (88.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]